Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)

Sumin Tang; Yuan Yin; Chaoyong Shen; Jiaju Chen; Xiaonan Yin; Bo Zhang; Yuqin Yao; Jinliang Yang; Zhixin Chen
April 2017
World Journal of Surgical Oncology;4/11/2017, Vol. 15, p1
Academic Journal
Background: Preoperative imatinib mesylate (IM) treatment has not yet been standardized. Here, we aim to further explore such therapy on patients with gastrointestinal stromal tumors (GIST) retrospectively. Methods: Patients experiencing preoperative IM were identified from January 2009 to February 2015. Results: A total of 28 GIST patients were identified. The patients received preoperative IM treatment for a median length of 13.5 months, ranging from 5 to 37 months. PR and SD were observed in 24 (85.7%) and 4 (15.3%) patients, respectively. The tumor shrinkage occurred predominantly within 6 to 12 months, and slight tumor shrinkage could be observed after 12 months in certain patients. Nineteen patients (67.9%) received surgery, and R0 resection was acquired in 18 (94.7%) patients. The initial mean maximum diameter was 10.5 (5.2 to 19.0) cm and decreased to 5.9 (2.7 to 19.0) cm after preoperative treatment with a median length of 12 (ranging from 5 to 36) months (P < 0.001) in patients receiving operations. Three in 7 cases of rectum GIST underwent abdominoperineal resection, and four others adopted sphincter-sparing resection. Partial gastrectomy was performed in four patients. Conclusions: IM prior to surgery can effectively prevent tumor rupture and facilitate surgery with low surgical morbidity for GIST patients. Tumor shrinkage following IM occurred predominantly within 6 to 12 months, and slight tumor shrinkage could be observed after 12 months in certain patients. In selected patients, prolonged exposure to IM is seemingly advisable under close radiological surveillance.


Related Articles

  • Imatinib.  // Reactions Weekly;2/6/2016, Vol. 1587 Issue 1, p152 

    An abstract of the article "Meckel's diverticulum harboring a rare gastrointestinal stromal tumor" by A.C. Berry and others is presented.

  • The role of imatinib plasma level testing in gastrointestinal stromal tumor. George, Suzanne; Trent, Jonathan // Cancer Chemotherapy & Pharmacology;Jan2011 Supplement, Vol. 67 Issue 1, p45 

    The management of patients with gastrointestinal stromal tumor (GIST) has markedly advanced over the past 10 years. Imatinib has exceptional activity in controlling gastrointestinal stromal tumor (GIST) due to inhibition of the constitutively active conformation of KIT and PDGFRA which is found...

  • Imatinib.  // Reactions Weekly;7/22/2006, Issue 1111, p12 

    The article presents a case study of a woman who developed acute cytolytic hepatitis during treatment with Imatinib for a tumour in her gastrointestinal stroma.

  • Imatinib.  // Reactions Weekly;Aug2014, Vol. 1512 Issue 1, p23 

    The article presents a case study of a patient who was admitted to hospital for jejunal gastrointestinal stromal tumour (GIST) and common variable immunodeficiency (CVID) after being treated with imatinib drug.

  • Adherence to Guidelines for Adjuvant Imatinib Therapy for GIST: A Multi-institutional Analysis. Bischof, Danielle; Dodson, Rebecca; Jimenez, M.; Behman, Ramy; Cocieru, Andrei; Blazer, Dan; Fisher, Sarah; Squires, Malcolm; Kooby, David; Maithel, Shishir; Groeschl, Ryan; Gamblin, T.; Bauer, Todd; Karanicolas, Paul; Law, Calvin; Quereshy, Fayez; Pawlik, Timothy // Journal of Gastrointestinal Surgery;Jun2015, Vol. 19 Issue 6, p1022 

    Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Adjuvant imatinib therapy improves recurrence-free and overall survival following surgery for patients with high-risk GIST; however, the factors associated with use of...

  • microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Akçakaya, P; Caramuta, S; Åhlen, J; Ghaderi, M; Berglund, E; Östman, A; Bränström, R; Larsson, C; Lui, W-O // British Journal of Cancer;11/25/2014, Vol. 111 Issue 11, p2091 

    Background:Gastrointestinal stromal tumour (GIST) is mainly initialised by receptor tyrosine kinase gene mutations. Although the tyrosine kinase inhibitor imatinib mesylate considerably improved the outcome of patients, imatinib resistance still remains a major therapeutic challenge in GIST...

  • Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea. Yoon-Koo Kang; Hye Jin Kang; Kyoung-Mee Kim; Taesung Sohn; Dongil Choi; Min-Hee Ryu; Woo Ho Kim; Han-Kwang Yang // Cancer Research & Treatment;Jun2012, Vol. 44 Issue 2, p85 

    Despite their rarity in incidence and prevalence, gastrointestinal stromal tumors (GISTs) have emerged as a distinct and noteworthy pathogenetic entity. The clinical management of GISTs has rapidly evolved due to the recent elucidation of their oncogenic signal transduction pathway and the...

  • Correlation between Computed Tomography and Pathological Findings of Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate. Ki Choon Sim; Beom Jin Park; Na Yeon Han; Deuk Jae Sung; Min Ju Kim; Sung Bum Cho; Hyun Kwon Ha; Hyoung Rae Kim // Journal of the Korean Society of Radiology;Nov2014, Vol. 71 Issue 5, p239 

    Purpose: To evaluate the correlation between pathological and computed tomography (CT) findings of gastrointestinal stromal tumors (GISTs) after imatinib mesylate (imatinib) treatment. Materials and Methods: Twenty-six patients with GIST (17 men, 9 women; mean age, 56 years) who underwent...

  • Peforated GIST in Jejunum -- A Rare Cause of Abdominal Cocoon. USHA M.; KUMAR, VIJAY; RAU AARATHI, R.; KAMATH, SULATHA // Journal of Clinical & Diagnostic Research;Mar2014, Vol. 8 Issue 3, p132 

    Gastrointestinal stromal tumours [GISTs] are rare but they commonly arise in stomach, and small or large intestines. They are usually accompanied with gastrointestinal bleeding. We are reporting a case of GIST which occurred in a 52-year-old male,who presented with acute abdomen. On laparotomy,...

  • Transsacral excision with pre-operative imatinib mesylate treatment and approach for gastrointestinal stromal tumors in the rectum: A report of two cases. LI-FENG SUN; JIN-JIE HE; SHAO-JUN YU; JING-HONG XU; JIAN-WEI WANG; JUN LI; YONG-MAO SONG; KE-FENG DING; SHU ZHENG // Oncology Letters;2014, Vol. 8 Issue 4, p1455 

    Gastrointestinal stromal tumors (GISTs) are rare in the rectum. Radical surgery, such as an abdominoperineal resection, is necessary for large rectal GISTs, which can result in the loss of function of involved organs. Imatinib mesylate can be used as perioperative therapy and may reduce tumor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics